H. Lee Moffitt Cancer Center And Research Institute
Clinical trials sponsored by H. Lee Moffitt Cancer Center And Research Institute, explained in plain language.
-
Experimental AML drug minnelide tested in early trial
Disease control TerminatedThis early-stage study tested the safety and best dose of a drug called Minnelide in 27 adults with acute myeloid leukemia (AML) that had returned or not responded to prior treatment. The study was stopped early, and its main goal was to find the highest safe dose and identify si…
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 01, 2026 16:00 UTC
-
Experimental drug siltuximab studied for rare leukemia
Disease control TerminatedThis early-phase study tested the drug siltuximab in 6 adults with large granular lymphocytic leukemia (LGLL), a rare blood cancer. The goal was to see if the drug is safe and can shrink or control the disease. The study was terminated early, so results are limited.
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
New hope for CLL patients: umbralisib shows promise in early trial
Disease control TerminatedThis study tested the experimental drug umbralisib in 12 people with chronic lymphocytic leukemia (CLL) who had not yet received treatment. The goal was to see how well the drug shrank or controlled the cancer and to check for side effects. The study was stopped early, but result…
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC